How to Buy Hims & Hers Health Stock
Hims & Hers Health Inc
Hims, Inc. manufactures men's wellness products. It offers products, including hair loss prevention medicines, sexual wellness products, skincare products, and oral care products.
Hims & Hers Health stock last closed at $33.10, down 5.54% from the previous day, and has increased 164.17% in one year. It has overperformed other stocks in the Household & Personal Products industry by 1.95 percentage points. Hims & Hers Health stock is currently +195.54% from its 52-week low of $11.20, and -54.65% from its 52-week high of $72.98.
As of Apr 30, 2025, there are 222.17M shares of HIMS outstanding. The market value of HIMS is $7.35B. In the last 24 hours, 38.32M HIMS shares were traded.
How to Buy Hims & Hers Health Stock
Not sure how to invest in Hims & Hers Health stock? Here's how.
- Figure out where to buy Hims & Hers Health stock: You need to decide on a stock brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you choose where to buy Hims & Hers Health stock.
- Create a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Fund your investment account: Pick your method of payment and add your details.
- Evaluate Hims & Hers Health stock: The Hims & Hers Health ticker symbol is HIMS. Is Hims & Hers Health stock a good investment? Should you buy shares of HIMS? How do HIMS's underlying business fundamentals look? Do top analysts think Hims & Hers Health is a good buy? Why has HIMS's stock price moved recently? (Hint: Our stock analysis website can help you decide if HIMS is a good stock to buy).
- Place your HIMS trade: Decide if you will purchase HIMS shares at the current market price or use a limit order to purchase HIMS stock at a given price.
- Get notifications regarding your HIMS position: Create a watchlist to get live updates on your investment in Hims & Hers Health stock.
Step 1: Figure out where to buy Hims & Hers Health stock
You need an online brokerage account in order to access the NYSE market and buy HIMS shares.
Our recommended brokerage: eToro
In our opinion, eToro is the best place to buy stocks. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to global markets: From Technology to Industrials, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro has a community with more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've chosen the best brokerage, it's time to fill out some personal information so you can invest in HIMS today.
How to Start a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal info to create a new brokerage account.
- Submit your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Fund your investment account
Now that you have opened your account on the best stock trading app, your next step is to transfer the money for your investment:
Watch this video walkthrough to see the process of transferring funds into your new brokerage account.
Step 4: Evaluate Hims & Hers Health stock
Once you have figured out the best place to buy Hims & Hers Health stock, it's absolutely critical to analyze their stock before you buy, so you actually understand the risk and opportunity.
Hims & Hers Health stock at a glance
Fundamentals of Hims & Hers Health
WallStreetZen was built to help part-time investors perform better fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on HIMS's stock page.
Is HIMS stock properly valued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge HIMS's fair value.
Using relative valuations methods:
- HIMS may be overvalued based on its P/E ratio of 57.07x, relative to Household & Personal Products industry P/E ratio of 25.5x
- HIMS may be overvalued based on its P/B ratio of 15.43x, relative to Household & Personal Products industry P/B ratio of 7.3x
- HIMS may be overvalued based on its PEG ratio of 1.62x
You can access more valuation research on HIMS's stock here.
HIMS Financial Overview
Positive Health Checks:
- HIMS's operating cash flow of $251.08M allows it to safely service it's debt of $11.35M.
- There are more short-term assets than long-term liabilities on the HIMS balance sheet.
- HIMS earnings of $71.71M is not enough to cover its interest payments.
- Total HIMS debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the HIMS balance sheet.
- HIMS profit margin has gone up from -2.7% to 8.5% in the past year.
Negative Health Checks:
- HIMS has a relatively high debt to equity ratio of 0.48.
Do analysts think it's a good time to buy HIMS stock
Out of 11 Wall Street analysts who track HIMS, the consensus analyst rating on Hims & Hers Health is a Hold
It's important to keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Latest HIMS Analyst Recommendations
Michael Cherny, a top 21% analyst from Leerink Partners maintains HIMS with a hold rating and raises their HIMS price target from $24.00 to $40.00, on Feb 25, 2025.
Korinne Wolfmeyer, a bottom 7% analyst from Piper Sandler maintains HIMS with a hold rating and raises their HIMS price target from $24.00 to $35.00, on Feb 25, 2025.
Ryan MacDonald, a bottom 8% analyst from Needham maintains HIMS with a buy rating and raises their HIMS price target from $31.00 to $61.00, on Feb 25, 2025.
Needham's Ryan MacDonald raised their price target on Hims & Hers Health (NYSE: HIMS) by 96.8% from $31 to $61 on 2025/02/25. The analyst maintained their Buy rating on the stock.
Hims & Hers Health reported its Q4 and FY 2024 earnings.
MacDonald noted that the quarter was "strong" but said the bigger news was last week's FDA announcement that the semaglutide shortage is over, which caused a selloff.
The analyst told readers that Needham sees this turn of events as "shortening the runway for revenue generation for the commercially available doses, a perspective different from that of Hims & Hers Health management, which sees a durable weight loss sales stream throughout FY 2025 supported by personalized semaglutide, oral weight loss offerings, and generic liraglutide (which will launch early in 2H 2025).
MacDonald pointed out that management's FY 2025 guidance was well above consensus on the assumption of $725M of weight loss revenue, above even the bull case Needham outlined in its 2025 top pick report.
Nevertheless, the analyst added that Needham "sees no reason to change its view and remains a buyer of the stock on weakness."
Earnings Report
Hims & Hers Health reported:
For Q4 2024:
- EPS of $0.11, which missed the Zacks Consensus Estimate of $0.12 but beat Q4 2023's $0.01.
- Revenue of $481.1M, which beat the Zacks Consensus Estimate by 2.1% and was up 95.1% Y/Y.
For FY 2024:
- EPS of $0.53, which missed the Zacks Consensus Estimate by 3.6% but beat FY 2023's $(0.11).
- Revenue of $1.48B, which beat the Zacks Consensus Estimate by 0.7% and was up 69.3% Y/Y.
Management guided:
For Q1 2025:
- Revenue of $520M to $540M.
For FY 2025:
- Revenue of $2.3B to $2.4B, representing 56% to 63% Y/Y growth.
CEO Andrew Dudum commented: “2024 was a fantastic year at Hims and Hers as we continue to build a platform that leverages personalization and technology unlike any traditional healthcare system.
“Over 2 million subscribers now entrust Hims & Hers to aid them in their journey to better health - with thousands more joining daily.
"In the coming years, we expect to further transform how individuals can improve their health with more comprehensive treatments, technologies that normalize unlimited follow-up support, and tools that can eventually be exported beyond Hims and Hers, enabling even more Americans to access this care.
"We believe an ongoing focus in these areas will allow every household in the country to access high quality, precision care that is convenient and affordable and expect 2025 will be another exciting step toward our vision of this next-generation of healthcare.”
Maria Ripps, a top 17% analyst from Canaccord Genuity maintains HIMS with a strong buy rating and raises their HIMS price target from $38.00 to $68.00, on Feb 19, 2025.
David Larsen, a bottom 10% analyst from BTIG initiates coverage on HIMS with a strong buy rating and announces their HIMS price target of $35.00, on Jan 7, 2025.
You can dive deeper into what analysts are projecting on the Hims & Hers Health stock forecast page.
HIMS Trading Indicators
HIMS Revenue
Last year, HIMS revenue was $1.48B. Over the past five year, HIMS's revenue has gone up by 78.03% per year. This was faster than the Household & Personal Products industry average of 3.85%.
Dig into HIMS's earnings and revenue performance here.
Are HIMS insiders buying or selling the stock?
In the last year, insiders at HIMS have sold more shares than they have bought.
Andrew Dudum, Chief Executive Officer of HIMS, was the latest HIMS insider to buy. They bought $121,500.00 worth of HIMS stock on Apr 29, 2025.
Dig into more about who owns HIMS shares here.
Does HIMS stock generate passive income?
No, Hims & Hers Health doesn't provide an income stream by paying out dividends.
Get opinions from other investors
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Place your HIMS trade
You have two primary options:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are usually the best for newer investors. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a specific price limit, place a limit order.
Press the Open Trade button and eToro will place the order.
If you require additional help investing in stocks on eToro, watch the how to video below:
Step 6: Get notifications regarding your HIMS position
Now that you own some HIMS stock, you'll want to keep up with your stock purchase.
Add HIMS to a watchlist to track your HIMS stock.
HIMS Feed
How to Buy Stock in Hims & Hers Health
To summarize, here are the 6 steps you need to take to buy Hims & Hers Health stock right now:
- Figure out where to buy Hims & Hers Health stock
- Create a brokerage account
- Fund your investment account
- Evaluate Hims & Hers Health stock
- Place your HIMS trade
- Get notifications regarding your HIMS position
If you need a place to buy stocks, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to get updates on your investment in Hims & Hers Health, create your watchlist below.
Other Articles You Might Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.